Selective binding to EGFR-positive breast cancer and other overexpressing tumor cell lines described for 425(scFv)-SNAP-AURIF and panitumumab-derived 1171(scFv)-SNAP-AURIF, was also confirmed on EGFR-positive breast cancer biopsies [149]. This evidence concerns the gene EGFR and neoplasm.